PTGX Stock Summary and Trading Ideas (Protagonist Therapeutics | NASDAQ:PTGX)

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Protagonist Therapeutics trades on the NASDAQ stock market under the symbol PTGX.

As of February 20, 2026, PTGX stock price declined to $82.76 with 554,675 million shares trading.

PTGX has a beta of -0.34, meaning it tends to be less sensitive to market movements. PTGX has a correlation of 0.01 to the broad based SPY ETF.

PTGX has a market cap of $5.15 billion. This is considered a Mid Cap stock.

Last quarter Protagonist Therapeutics reported $5 million in Revenue and -$.62 earnings per share. This fell short of revenue expectation by $-2 million and met earnings estimates .

In the last 3 years, PTGX traded as high as $96.54 and as low as $13.72.

The top ETF exchange traded funds that PTGX belongs to (by Net Assets): IJR, VTI, IWM, XBI, VB.

PTGX has outperformed the market in the last year with a return of +115.0%, while the SPY ETF gained +14.1%. However, in the most recent history, PTGX shares have underperformed the stock market with its stock returning -1.7% in the last 3 month period and -2.0% for the last 2 week period, while SPY has returned +6.0% and -0.2%, respectively.

PTGX support price is $80.95 and resistance is $85.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTGX shares will trade within this expected range on the day.